JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB237734

Anti-C1GALT1 antibody

Be the first to review this product! Submit a review

|

(6 Publications)

Rabbit Polyclonal C1GALT1 antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human samples. Cited in 6 publications. Immunogen corresponding to Recombinant Fragment Protein within Human C1GALT1 aa 1-150.

View Alternative Names

Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1, B3Gal-T8, Core 1 O-glycan T-synthase, C1GalT1, Core 1 beta3-Gal-T1, C1GALT1

4 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C1GALT1 antibody (AB237734)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C1GALT1 antibody (AB237734)

Paraffin-embedded human kidney tissue stained for C1GALT1 using ab237734 at 1/1000 dilution in immunohistochemical analysis.

After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C1GALT1 antibody (AB237734)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C1GALT1 antibody (AB237734)

Paraffin-embedded human colon cancer tissue stained for C1GALT1 using ab237734 at 1/1000 dilution in immunohistochemical analysis.

After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

Immunocytochemistry/ Immunofluorescence - Anti-C1GALT1 antibody (AB237734)
  • ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-C1GALT1 antibody (AB237734)

HepG2 (human liver hepatocellular carcinoma cell line) cells stained for C1GALT1 (green) using ab237734 at 1/333 dilution in ICC/IF, followed by Alexa Fluor 488® conjugated Goat Anti-Rabbit IgG (H+L). The nuclear counter stain is DAPI.

The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C.

Western blot - Anti-C1GALT1 antibody (AB237734)
  • WB

Supplier Data

Western blot - Anti-C1GALT1 antibody (AB237734)

All lanes:

Western blot - Anti-C1GALT1 antibody (ab237734) at 1/500 dilution

Lane 1:

U-251 MG (human brain glioma cell line) whole cell lysate

Lane 2:

HepG2 (human liver hepatocellular carcinoma cell line) whole cell lysate

Secondary

All lanes:

Goat polyclonal to rabbit IgG at 1/50000 dilution

Predicted band size: 42 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB, IHC-P, ICC/IF

applications

Immunogen

Recombinant Fragment Protein within Human C1GALT1 aa 1-150. The exact immunogen used to generate this antibody is proprietary information.

Q9NS00

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/500 - 1/1000", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/5000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/200 - 1/500", "ICCIF-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein G
Purification notes
Purity >95%.
Storage buffer
pH: 7.4 Preservative: 0.03% Proclin 300 Constituents: PBS, 50% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

C1GALT1 also known as core 1 β13-galactosyltransferase is an enzyme important for the synthesis of core 1 O-glycans. The enzyme has a molecular mass of approximately 55 kDa. It localizes in the Golgi apparatus where it actively participates in glycosylation processes. C1GALT1 shows widespread expression in various tissues including the liver lungs and intestines. By catalyzing the transfer of galactose to N-acetylgalactosamine on proteins it plays an important role in O-glycan biosynthesis.
Biological function summary

The function of C1GALT1 extends to modifying proteins that impact cell-cell interactions protein stability and signaling pathways. C1GALT1 does not work alone but as a part of a complex with chaperone protein COSMC which is necessary for its glycosyltransferase activity. This complex formation is essential to ensure the proper structure and function of the resulting glycoproteins which have a broad range of impacts in cell biology and communication.

Pathways

C1GALT1 plays a significant role in the mucin-type O-glycan biosynthesis pathway which is critical for producing mucins. These proteins are important for protective mucus barriers in several organs. C1GALT1 shows interaction with galectin proteins that recognize specific glycan structures influencing cellular processes such as adhesion and migration. Additionally it participates in the PI3K-Akt signaling pathway which links to cell growth and survival often intersecting with pathways involving other glycosyltransferases.

C1GALT1 has associations with IgA nephropathy also known as Berger's disease where abnormal glycosylation patterns of IgA1 occur. This disorder often involves the misfunction of proteins like C1GALT1 and COSMC. Furthermore aberrant C1GALT1 activity may have links to cancer progression as improper glycosylation can impact tumor cell migration and invasion. C1GALT1's interplay with galectins and other glycoproteins influences these pathological conditions making it a focal point for understanding and potentially targeting these diseases.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Glycosyltransferase that generates the core 1 O-glycan Gal-beta1-3GalNAc-alpha1-Ser/Thr (T antigen), which is a precursor for many extended O-glycans in glycoproteins (PubMed : 11677243). Plays a central role in many processes, such as angiogenesis, thrombopoiesis and kidney homeostasis development (By similarity).
See full target information C1GALT1

Publications (6)

Recent publications for all applications. Explore the full list and refine your search

Journal of cancer research and clinical oncology 150:214 PubMed38662050

2024

High core 1β1,3-galactosyltransferase 1 expression is associated with poor prognosis and promotes cellular radioresistance in lung adenocarcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Yong Chen,Yanyan Ji,Lin Shen,Ying Li,Yue Ren,Hongcan Shi,Yue Li,Yunjiang Wu

Molecular medicine reports 25: PubMed35485284

2022

TXNDC9 knockdown inhibits lung adenocarcinoma progression by targeting YWHAG.

Applications

Unspecified application

Species

Unspecified reactive species

Jing Wang,Xiaotao Pan,Jie Li,Jin Zhao

American journal of nephrology 53:10-20 PubMed34965524

2021

Development of Urinary Diagnostic Biomarker for IgA Nephropathy by Lectin Microarray.

Applications

Unspecified application

Species

Unspecified reactive species

Yasuhiro Onishi,Koki Mise,Chieko Kawakita,Haruhito A Uchida,Hitoshi Sugiyama,Ryosuke Sugawara,Satoshi Yamaguchi,Michihiro Yoshida,Toshiharu Mitsuhashi,Masao Yamada,Jun Hirabayashi,Jun Wada

Cell & bioscience 11:166 PubMed34452648

2021

A novel mechanism for C1GALT1 in the regulation of gastric cancer progression.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoxia Dong,Chunli Chen,Xinzhou Deng,Yongyu Liu,Qiwen Duan,Zhen Peng,Zhiguo Luo,Li Shen

Frontiers in cell and developmental biology 9:707970 PubMed34307388

2021

C1GALT1, Negatively Regulated by miR-181d-5p, Promotes Tumor Progression via Upregulating RAC1 in Lung Adenocarcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoxia Dong,Yongyu Liu,Xinzhou Deng,Jun Shao,Shuangyue Tian,Shuang Chen,Rongxin Huang,Ziao Lin,Chunli Chen,Li Shen

Frontiers in immunology 11:563699 PubMed33324395

2020

microRNA-630 Regulates Underglycosylated IgA1 Production in the Tonsils by Targeting TLR4 in IgA Nephropathy.

Applications

Unspecified application

Species

Unspecified reactive species

Chan Liu,Mu-Yao Ye,Wen-Zhe Yan,Xiao-Fei Peng,Li-Yu He,You-Ming Peng
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com